The Latest, Most Promising Treatments
Roswell Park’s strong research program means eligible patients can enroll in clinical trials of cutting-edge treatments that are not widely available — some are available nowhere else — including a range of immunotherapies.
Nationally Recognized Experts Who Help Set the Standards
Patients who come to Roswell Park for blood or marrow transplant or cellular therapy are in good hands.
Philip McCarthy, MD, Director of the Transplant & Cellular Therapy Center, has more than 20 years of experience caring for stem cell transplant patients and directing clinical trials focused on improving the transplant process to extend survival and reduce side effects. He led a major study that changed the standard of care for multiple myeloma patients to improve their chances of survival.
Kunle Odunsi, MD, PhD, Deputy Director of Roswell Park and Executive Director of the Center for Immunotherapy, was elected in 2018 to membership in the elite National Academy of Medicine, a body that provides national and international guidance on issues relating to health and medicine. He was chosen for the honor in part for his “pioneering studies to re-engineer mature T cells and hematopoietic stem cells for adoptive T-cell therapy.”
Advanced Training for Delivering Cellular Therapies, Including BMT
Cellular therapies, including blood or marrow transplant (BMT), can cause specific types of side effects. All our clinical staff members who care for patients receiving cellular therapies undergo rigorous training in Risk Evaluation & Mitigation Strategies (REMS) through the Food & Drug Administration (FDA), to reduce the risk of side effects and address them quickly and appropriately if they do occur.
One of the Nation’s Top Centers for BMT (Stem Cell Transplant)
Roswell Park was among the first centers in the world to routinely offer blood and marrow (stem cell) transplants, and we consistently have excellent patient survival results. Over a seven-year period, our patients who underwent allogeneic transplant (involving a donor) had either comparable or significantly better-than-predicted survival compared to what would be expected based on patient age, other existing health problems, whether or not the patient was in remission at the time of transplant and how closely the patient was matched to the donor.
All BMT candidates are seen within one week of referral to Roswell Park. In cases where timing is especially crucial, patients are seen within 24 hours.
An Extra Measure of Safety and Confidence
We are accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) for both cellular therapies and blood and marrow transplant (BMT). This signifies that our program meets or exceeds the highest standards of safety in cell collection and transplantation, and that our staff members have the education, training and experience to provide our patients the specialized care they need.
Pathology Expertise for Early Detection of GVHD
Our pathologists are especially skilled in identifying the signs of graft-versus-host disease (GVHD), a serious complication of blood and marrow transplant (BMT). They are able to identify GVHD early on, when it can be treated more easily.